global life sciences trends and opportunities 2012-2015
TRANSCRIPT
Global Life Sciences Trends and Opportunities
2012–2015
Global Team Identifies Highlights Across
Pharmaceutical/Biotechnology, Diagnostics, and Research Industries
November 2012
NB98
NB98 2
Why You Need to Know the Big Picture
As a pharma/biotech, in vitro diagnostic, or life science research industry leader,
have you ever asked yourself the following questions:
o How do changes in the pharmaceutical industry trickle down to the diagnostics and life
sciences industries?
o Which segments across pharma/biotech, diagnostics, and life sciences will be the
highest growth markets by 2015?
o Which companies are successful in the pharma/biotech, diagnostics, and life sciences
markets and why? Does success in one market translate to success in another?
o Is it the right time for your company to enter another life sciences market or segment?
What are the prime opportunities and what are the risks?
o Which non-traditional companies are entering life sciences markets?
o What is impeding the growth of an „emerging‟ market?
o What are the defining trends in the healthcare markets for 2012 and how this will
change in 2015?
NB98 3
What you will find in this deliverable
Abstract:
The new Frost & Sullivan research deliverable titled “Global Life Sciences Trends and
Opportunities 2012-2015” analyzes critical trends and opportunities for 2012-2015 in the
pharmaceutical/biotechnology, diagnostics, and life sciences research industries. It sources
30+ Frost & Sullivan proprietary research deliverables across the United States, Europe,
Brazil, Russia, Indonesia, Vietnam, and Sub-Saharan Africa representing over 100 primary
interviews with industry leaders, key opinion leaders (KOLs) and end users. Example
analyses include growth areas now and developing, companies to watch, and a 2015 outlook
for global healthcare.
Topics Covered:
• Daunting Challenges for the Pharmaceutical Industry
• Pharma‟s New Growth Strategies
• Curbing the Costs of Drug Development (Pharmaceutical Outsourcing)
• Lean Laboratories-Doing More With Less
• Novel Biomarker Discovery Leading to Novel Therapeutics
• Genetic Technologies are Integral to Healthcare
• The Last Word-4 Major Predictions for the Industry
NB98 4
• Biologics are an industry innovation that continues to grow due
to their high degree of efficacy.
• Indications with high unmet need like complex disease and
orphan disease are key opportunities.
• Pharmaceutical outsourcing of clinical trials, manufacturing,
and biosimilars development will continue to curb unsustainable
costs of making drugs.
• Targeted therapies and companion diagnostics are prevalent
in the treatment of cancer and some infectious diseases.
• Generic pharmaceuticals in emerging markets improve access
to healthcare within growing economies.
• Modern healthcare is rapidly adopting molecular diagnostics
and will soon adopt next generation sequencing.
• Advanced tools enable single-cell analysis in R&D and
diagnostics.
• MicroRNA and epigenetics in disease fuel growth in tools and
diagnostic tests.
• Affordable, “personal,” low-throughput instruments are well
matched to R&D budgets and improve access.
Life Science Growth Areas: Now and Developing
Recommended Growth Areas Now (2012) Future Markets With Strong Potential (2015)
• Biosimilars and biobetters will mature in the United
States.
• Targeted therapies and companion diagnostics
will grow in disease other than cancer and
infectious disease like diabetes and cholesterol
control (e.g., statins).
• MicroRNA therapeutics will emerge as a result of
field advancement in microRNA tools and
microRNA as biomarkers.
• Affordable healthcare (generics and point-of-care-
testing) will usher in next wave emerging markets
like Indonesia and Vietnam.
Source: Frost & Sullivan analysis.
Can you afford to miss the ‘next big thing’?
NB98 5
Defining Healthcare Trends in the Future
Source: Frost & Sullivan analysis.
Topic Present (2012) Future Outlook (2015)
Clinical trial
requirements
Clinical trials for new drugs center on
basic requirements such as
comparison with placebo.
Clinical trials will have more requirements like more effective
treatment of the disease itself rather than just symptoms in
addition to comparison with placebo. This trend is driven by
demands from payers for reimbursement.
Price of
Biologics
Biologics are expensive therapies with
little competition.
Increasing pressure on the soaring costs of biologics will be
effective in stabilizing the rate of price increase.
Miniaturization Nanotechnology and microfluidics
enable a miniaturization trend in R&D
and diagnostics.
Laboratories will be equipped with stripped-down, lower
throughput, “personal” instruments that have advantages like a
smaller footprint and smaller price tags.
Providers of
Advanced
Technologies
Advanced fields like next generation
sequencing, oncology, and genomic
analysis are becoming more
centralized.
There will be even greater consolidation of advanced testing,
regardless of technology, as there is no strong need to have it
at the regional level.
Big Data in
Genomic
Research
Genomic researchers are facing
interpretation issues of genomic
databases and differentiating what is
or is not clinically useful.
Genomic researchers will address more and more big data
issues like storage and database management.
Personal
Genomic Data
Genomic analysis is conducted and
performed primarily for the individual
patients‟ needs.
Physicians may aggregate individual patient case data to
leverage daily practice findings in a sample population. This
may be particularly useful in rare indications.
How will your company meet the future needs of the industry?
NB98 6
Contact
Britni MyersExecutiveHealthcare Corporate Communications
(210) 477-8481
NB98 7
Global Perspective40+ Offices Monitoring for Opportunities and Challenges
NB98 8
Industry ConvergenceComprehensive Industry Coverage Sparks Innovation Opportunities
Automotive&
Transportation
Aerospace & Defense Measurement &
Instrumentation
Information &
Communication Technologies
HealthcareEnvironment & Building
Technologies
Energy & Power
Systems
Chemicals, Materials
& Food
Electronics &
Security
Industrial Automation
& Process Control
Automotive
Transportation & Logistics
Consumer
Technologies
Minerals & Mining